ALK expands Catalent manufacturing partnership with DKK 500m investment in allergy tablet capacity
ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets.
The three-year investment programme is expected to add around 300 million tablets of annual capacity, taking potential production to approximately 1.1 billion tablets from the early 2030s.
The expanded partnership also secures long-term access to Catalent's Zydis technology and could support future peanut and tree-nut allergy tablet programmes.
Field | Content |
Article Type | Deals |
Companies | ALK; Catalent |
Deal Type | Strategic manufacturing partnership expansion |
Investment | Approximately DKK 500 million over three years |
Technology/Platform | Catalent Zydis fast-dissolving tablet technology |
Therapy Areas | Allergy; immunotherapy |
Manufacturing Scope | Allergy immunotherapy tablets |
Additional Annual Capacity | Approximately 300 million tablets |
Expected Total Annual Capacity | Approximately 1.1 billion tablets from the early 2030s |
Potential Future Programmes | Peanut and tree-nut allergy tablets |
What Happened | ALK expanded its manufacturing partnership with Catalent through a DKK 500 million investment programme. |
Why It Matters | The agreement materially increases production capacity for ALK's tablet-based allergy immunotherapy portfolio and secures long-term access to a specialised drug-delivery platform. |
Supporting Context | Catalent's Zydis technology is used for rapidly dissolving oral tablets and forms part of ALK's existing allergy tablet manufacturing network. |
Strategic Rationale | ALK is expanding capacity ahead of anticipated long-term demand and potential launches in additional allergy indications. |
Potential Impact | Higher capacity could support wider global access to allergy immunotherapy tablets and future expansion into food-allergy treatment. |
Key Takeaway | ALK is committing around DKK 500 million to increase annual allergy-tablet capacity to approximately 1.1 billion units. |
What to Watch | Capacity build-out, future product launches and development of peanut and tree-nut allergy tablets. |
Primary Source | ALK |
Relevant Date | 30 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare